Is Pharvaris N.V. (PHVS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 16.7% / 30% | 0.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 16.7% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.3% / 33% | 96.3% / 33% | 1.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 16.7% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.3% / 33% | 96.3% / 33% | 1.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -53.8% | |
| Return on Assets (ROA) | -32.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$120M |
| Free Cash Flow | -$121M |
| Total Debt | $861,470 |
| Debt-to-Equity | 0.2 |
| Current Ratio | 12.9 |
| Total Assets | $291M |
Price & Trading
| Last Close | $27.39 |
| 50-Day MA | $26.89 |
| 200-Day MA | $23.79 |
| Avg Volume | 154K |
| Beta | -2.7 |
|
52-Week Range
$11.51
| |
About Pharvaris N.V. (PHVS)
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Pharvaris N.V. (PHVS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Pharvaris N.V. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Pharvaris N.V.'s debt ratio?
Pharvaris N.V.'s debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.3%.
What are Pharvaris N.V.'s key financial metrics?
Pharvaris N.V. has a market capitalization of $1.8B. Return on equity stands at -53.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.